Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of a CMV-MVA Triplex Vaccine in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant

NCT02506933 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT02506933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02506933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of a CMV-MVA Triplex Vaccine in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 21, 2015
Completion date
May 10, 2027
Enrollment
102 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

accelerated phase chronic myelogenous leukemia, bcr-abl1 positive, acute lymphoblastic leukemia in remission, acute myeloid leukemia in remission, chronic lymphocytic leukemia, chronic phase chronic myelogenous leukemia, bcr-abl1 positive, cytomegaloviral infection, hodgkin lymphoma, lymphadenopathy, lymphoblastic lymphoma, myelodysplastic syndrome, myelofibrosis, myeloproliferative neoplasm, non-hodgkin lymphoma